March 20, 2017

Novocure Receives MHLW Approval for Second Generation Optune® in Japan

Second generation Optune is now approved in all active Novocure markets Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that… Read More
learn more
March 20, 2017

Novocure Receives MHLW Approval for Second Generation Optune® in Japan

Second generation Optune is now approved in all active Novocure markets Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that… Read More
learn more
March 1, 2017

Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting 2017

Five-year survival analysis from the EF-14 phase 3 pivotal trial evaluating TTFields in combination with temozolomide for newly diagnosed glioblastoma to be shared in an oral presentation PANOVA clinical data to be presented evaluating TTFields in combination with standard chemotherapy for advanced pancreatic cancer INNOVATE… Read More
learn more
March 1, 2017

Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting 2017

Five-year survival analysis from the EF-14 phase 3 pivotal trial evaluating TTFields in combination with temozolomide for newly diagnosed glioblastoma to be shared in an oral presentation PANOVA clinical data to be presented evaluating TTFields in combination with standard chemotherapy for advanced pancreatic cancer INNOVATE… Read More
learn more